JP7846761B2 - モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法 - Google Patents

モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法

Info

Publication number
JP7846761B2
JP7846761B2 JP2024525160A JP2024525160A JP7846761B2 JP 7846761 B2 JP7846761 B2 JP 7846761B2 JP 2024525160 A JP2024525160 A JP 2024525160A JP 2024525160 A JP2024525160 A JP 2024525160A JP 7846761 B2 JP7846761 B2 JP 7846761B2
Authority
JP
Japan
Prior art keywords
mosnetuzumab
approximately
dose
lenalidomide
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024525160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540044A (ja
JP2024540044A5 (https=
Inventor
キャサリン グラニエール，
アンドレア ナップ，
ジーチョン リー，
キャロル エレイン オヘア，
エンツェツェグ ピューレフ，
マイケル シー． ウェイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2024540044A publication Critical patent/JP2024540044A/ja
Publication of JP2024540044A5 publication Critical patent/JP2024540044A5/ja
Priority to JP2025155232A priority Critical patent/JP2026004356A/ja
Application granted granted Critical
Publication of JP7846761B2 publication Critical patent/JP7846761B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024525160A 2021-10-29 2021-10-29 モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法 Active JP7846761B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025155232A JP2026004356A (ja) 2021-10-29 2025-09-18 モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/057439 WO2023075798A1 (en) 2021-10-29 2021-10-29 Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025155232A Division JP2026004356A (ja) 2021-10-29 2025-09-18 モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法

Publications (3)

Publication Number Publication Date
JP2024540044A JP2024540044A (ja) 2024-10-31
JP2024540044A5 JP2024540044A5 (https=) 2025-05-20
JP7846761B2 true JP7846761B2 (ja) 2026-04-15

Family

ID=86158448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024525160A Active JP7846761B2 (ja) 2021-10-29 2021-10-29 モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法
JP2025155232A Pending JP2026004356A (ja) 2021-10-29 2025-09-18 モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025155232A Pending JP2026004356A (ja) 2021-10-29 2025-09-18 モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法

Country Status (7)

Country Link
JP (2) JP7846761B2 (https=)
KR (1) KR20240093915A (https=)
AU (1) AU2021471006A1 (https=)
CA (1) CA3236111A1 (https=)
MX (1) MX2024005105A (https=)
PE (1) PE20241211A1 (https=)
WO (1) WO2023075798A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026009843A (ja) * 2024-06-25 2026-01-21 ジェネンテック， インコーポレイテッド 単剤療法としてまたはレナリドミドと組み合わせたモスネツズマブの皮下投与を用いてがんを処置する方法
WO2026050474A1 (en) * 2024-08-28 2026-03-05 Genentech, Inc. Subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin for use in treating non-hodgkin's lymphoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232169A1 (en) 2019-05-14 2020-11-19 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232169A1 (en) 2019-05-14 2020-11-19 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Blood，2020年11月05日，Vol. 136, No. Supplement 1，p.37-38，DOI: 10.1182/blood-2020-136295
Blood，2020年11月05日，Vol. 136, No. Supplement 1，p.42-44，DOI: 10.1182/blood-2020-135839
Hoffmann-La Roche，A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (Celestimo)，The ClinicalTrials.gov，NCT04712097，2021年10月20日，[2025年6月17日検索]，インターネット＜ＵＲＬ：https://clinicaltrials.gov/study/NCT04712097?tab=history&a=11#version-content-panel＞
Journal of Clinical Oncology，2021年05月20日，Vol. 39, No. 15_suppl，p.7520-7520，DOI: 10.1200/JCO.2021.39.15_suppl.7520

Also Published As

Publication number Publication date
JP2024540044A (ja) 2024-10-31
PE20241211A1 (es) 2024-06-06
CA3236111A1 (en) 2023-05-04
WO2023075798A9 (en) 2023-06-29
KR20240093915A (ko) 2024-06-24
AU2021471006A1 (en) 2024-05-16
MX2024005105A (es) 2024-05-14
JP2026004356A (ja) 2026-01-14
WO2023075798A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
KR20220133243A (ko) 항 tigit 길항제 항체를 이용한 암의 치료 방법
JP2026004356A (ja) モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法
TW202228791A (zh) 以抗ｃｄ２０／抗ｃｄ３雙特異性抗體和抗ｃｄ７９ｂ抗體藥物結合物治療的給藥方法
TW202225192A (zh) 用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
US20240287182A1 (en) Methods and compositions for treating cancer
US20260055204A1 (en) Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
CN119546334A (zh) 用于利用莫苏尼妥珠单抗和来那度胺治疗先前未治疗的滤泡性淋巴瘤的方法
US20230190932A1 (en) Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide
US20260078198A1 (en) Methods for treating cancer using subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin
TW202132344A (zh) 用於治療血液癌症之診斷及治療方法
TW202348626A (zh) 用莫蘇妥珠單抗及來那度胺治療復發性／難治性濾泡性淋巴瘤之方法
US20260109777A1 (en) Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide
HK40110052A (zh) 用於治疗癌症的方法和组合物
TW202320848A (zh) 治療癌症之方法及組成物
HK40105861A (zh) 用莫苏尼妥珠单抗和维泊妥珠单抗治疗cd20阳性增殖性疾患的方法
HK40106740A (zh) 用抗cd20/抗cd3双特异性抗体进行治疗的给药
HK40102568A (zh) 用於使用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物的治疗的给药

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240626

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20240725

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20240725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260403

R150 Certificate of patent or registration of utility model

Ref document number: 7846761

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150